Diagnosis and Management of Autoimmune Myasthenia Gravis

被引:17
|
作者
Angelini, Corrado [1 ,2 ]
机构
[1] Univ Padua, Dept Neurosci, I-35128 Padua, Italy
[2] IRCSS S Camillo, Venice, Italy
关键词
QUALITY-OF-LIFE; ACETYLCHOLINE-RECEPTOR; MYCOPHENOLATE-MOFETIL; NEUROMUSCULAR-TRANSMISSION; MUSK ANTIBODIES; DOUBLE-BLIND; PYRIDOSTIGMINE; PATIENT; TRIAL; MG;
D O I
10.2165/11584740-000000000-00000
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Earlier diagnosis and the availability of effective treatments have reduced the burden of high mortality and severe disability previously associated with myasthenia gravis (MG). Consequently, the prognosis of MG is now much improved. However, despite extensive knowledge of MG and its aetiology, diagnosing the disease remains problematic and can be delayed because of its nonspecific and fluctuating symptoms, and the management of MG is associated with considerable limitations. Current treatments based on immunomodulation are associated with adverse effects arising from prolonged immune suppression. There is a need for improved awareness among primary caregivers about this relatively rare, but treatable, disease.
引用
收藏
页码:1 / 14
页数:14
相关论文
共 50 条
  • [1] Diagnosis and Management of Autoimmune Myasthenia Gravis
    Corrado Angelini
    Clinical Drug Investigation, 2011, 31 : 1 - 14
  • [2] Advances in autoimmune myasthenia gravis management
    Wang, Shuhui
    Breskovska, Iva
    Gandhy, Shreya
    Punga, Anna Rostedt
    Guptill, Jeffery T.
    Kaminski, Henry J.
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2018, 18 (07) : 573 - 588
  • [3] Italian recommendations for the diagnosis and treatment of myasthenia gravis
    Evoli, Amelia
    Antonini, Giovanni
    Antozzi, Carlo
    DiMuzio, Antonio
    Habetswallner, Francesco
    Iani, Cesare
    Inghilleri, Maurizio
    Liguori, Rocco
    Mantegazza, Renato
    Massa, Roberto
    Pegoraro, Elena
    Ricciardi, Roberta
    Rodolico, Carmelo
    NEUROLOGICAL SCIENCES, 2019, 40 (06) : 1111 - 1124
  • [4] Treatment principles in the management of autoimmune myasthenia gravis
    Richman, DP
    Agius, MA
    MYASTHENIA GRAVIS AND RELATED DISORDERS: BIOCHEMICAL BASIS FOR DISEASE OF THE NEUROMUSCULAR JUNCTION, 2003, 998 : 457 - 472
  • [5] Ephedrine treatment for autoimmune myasthenia gravis
    Lipka, Alexander F.
    Vrinten, Charlotte
    van Zwet, Erik W.
    Schimmel, Kirsten J. M.
    Cornel, Martina C.
    Kuijpers, Marja R.
    Hekster, Yechiel A.
    Weinreich, Stephanie S.
    Verschuuren, Jan J. G. M.
    NEUROMUSCULAR DISORDERS, 2017, 27 (03) : 259 - 265
  • [6] Autoimmune mechanisms in myasthenia gravis
    Cavalcante, Paola
    Bernasconi, Pia
    Mantegazza, Renato
    CURRENT OPINION IN NEUROLOGY, 2012, 25 (05) : 621 - 629
  • [7] Juvenile myasthenia gravis
    Papazian, Oscar
    Alfonso, Israel
    Araguez, Nayle
    MEDICINA-BUENOS AIRES, 2009, 69 (01) : 71 - 83
  • [8] Autoimmune Thyroiditis and Myasthenia Gravis
    Lopomo, Angela
    Berrih-Aknin, Sonia
    FRONTIERS IN ENDOCRINOLOGY, 2017, 8
  • [9] Novel pathophysiological insights in autoimmune myasthenia gravis
    Masi, Gianvito
    O'Connor, Kevin C.
    CURRENT OPINION IN NEUROLOGY, 2022, 35 (05) : 586 - 596
  • [10] Clinical and biological heterogeneity of autoimmune myasthenia gravis
    Pal, Jozsef
    Rozsa, Csilla
    Komoly, Samuel
    Illes, Zsolt
    JOURNAL OF NEUROIMMUNOLOGY, 2011, 231 (1-2) : 43 - 54